Lupin

Estimate change	↓
TP change	⟷
Rating change	⟷

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USDb)	1080.7 / 11.4
52-Week Range (INR)	2530 / 1852
1, 6, 12 Rel. Per (%)	-6/13/22
12M Avg Val (INR M)	2226

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	279.6	318.8	343.2
EBITDA	81.6	81.6	81.1
Adj. PAT	53.3	47.2	51.9
EBIT Margin (%)	24.6	19.9	19.2
Cons. Adj. EPS (INR)	116.5	103.1	113.6
EPS Gr. (%)	62.9	-11.5	10.1
BV/Sh. (INR)	491.0	610.5	721.2
Ratios			
Net D:E	0.0	-0.1	-0.2
RoE (%)	26.9	18.7	17.1
RoCE (%)	21.7	16.0	15.2
Payout (%)	2.5	2.8	2.6
Valuations			
P/E (x)	20.3	22.9	20.8
EV/EBITDA (x)	13.6	13.2	12.6
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	4.1	2.6	5.2
EV/Sales (x)	4.0	3.4	3.0

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	46.9	46.9	46.9
DII	24.7	25.3	25.6
FII	22.4	21.7	21.3
Others	6.1	6.1	6.3

FII includes depository receipts

CMP: INR2,364 **TP: INR2,500 (+6%)** **Neutral**

Execution drives another earnings beat

Building long-term growth drivers amid near-term earnings consolidation

- Lupin (LPC) has delivered a better-than-expected financial performance in 1QFY27, with 5%/15% beat on revenue/EBITDA. Compared to the EBITDA beat, the PAT beat was lower because of higher depreciation and tax rate.
- Segment-wise, other developed markets and emerging markets surprised considerably on the revenue front. Domestic formulation (DF) and the US business were marginally better than expectations.
- US business remains on strong footing with stable business from niche opportunities and volume growth in base business.
- Ex-US, organic revenue growth was 20% YoY in 1QFY27.
- LPC's DF business with 15% YoY growth continued to outperform the industry with IPM YoY growth of 13.5%. LPC sustained leadership in chronic therapies through new launches and strong brand recall of existing products.
- We reduce our earnings estimate by 6% for FY27 to factor in increased depreciation and a higher tax rate. We value LPC at 22x 12-month forward earnings to arrive at a TP of INR2,500.
- FY27 would be the year of consolidation after three years of strong earnings growth. LPC is implementing efforts to build a niche product pipeline in focus markets to improve the growth outlook going forward. This, supported with marketing efforts in select markets, is expected to strengthen overall growth for the company.
- Having said this, earnings is expected to remain stable over FY26-28 due to increased competition in certain products in the near term and some gestation period to offset this impact, and subsequently return to growth path. The valuation provides limited upside from the current levels. Maintain Neutral.

Product mix drives profitability

- 1QFY27 revenue grew 32% YoY to INR82.8b (our est. INR78.9b).
- Gross margin (GM) expanded 310bp YoY to 74.8%.
- EBITDA margin expanded 360bp YoY to 29.8% (est. 27.2%), largely due to better GM.
- As a result, EBITDA grew 50.1% YoY to INR24.6b (our est. INR21.5b).
- Adj. PAT grew 24.4% YoY to INR14.2b (our est.: INR13.6b), lagging EBITDA growth due to higher depreciation, interest expense, and effective tax rate.

Broad-based growth across geographies

- US sales grew 43% YoY to INR34.3b (+30% in cc to USD366m; 42% of sales).
- DF sales grew 13.9% YoY to INR23.8b (29% of sales).
- Other developed market sales grew 48.3% YoY to INR11.5b (14% of sales).
- Emerging market sales grew 51.7% YoY to INR9.9b (12% of sales).
- API sales increased 8.5% YoY to INR2.6b (3% of sales).
- LPC received six ANDA approvals and launched three products in 1QFY27.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com) | **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)
Vipul Mehta - Research Analyst (vipul.mehta@motilaloswal.com) | **Khyati Sonthalia - Research Analyst** (khyati.sonthalia@motilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- LPC launched seven brands across therapies in India during the quarter and plans to launch 20+ products in FY27.
- DF reported 6.1% volume growth in 1QFY27, with the chronic portfolio's contribution increasing to ~67% from ~65% in FY26.
- R&D expenditure stood at INR6.1b (7.4% of sales) in 1QFY27.
- Capex stood at INR2.8b (3.4% of sales) in 1QFY27.

Highlights from the management commentary

- LPC reiterated FY27 guidance of high-single-digit revenue growth with ~25% EBITDA margin.
- Management guided FY27 R&D spend at ~8% of sales and the effective tax rate at 27–28%.
- Management expects 10-20% growth in Europe, led by its product pipeline. South Africa is expected to grow at a relatively slower pace; double-digit growth is expected to continue across the RoW markets.
- Management guided FY27 US business revenue at USD1.1-1.2b.
- LPC expects quarterly US revenue of USD250-280m in the next few quarters, reflecting pricing and market share pressure in Tolvaptan and Mirabegron.
- Management indicated Tolvaptan competition will increase from 2Q, with Apotex and Teva entering the market and a potential fourth entrant by Sep'26, resulting in pricing pressure and market share redistribution, although the market may expand with ~40% generic conversion currently.
- Management expects the US business to return to its growth trajectory from FY28, aided by exclusive first-to-file opportunities, biosimilars and 505(b)(2) products.

Consolidated - Quarterly Earnings

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	% Var
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	
Net Sales	**62,684**	**70,475**	**71,675**	**74,747**	**82,769**	**81,297**	**78,065**	**76,634**	**2,79,580**	**3,18,766**	**78,897**	4.9
YoY Change (%)	11.9	27.1	25.9	31.9	32.0	15.4	8.9	2.5	24.2	14.0	25.9	
Total Expenditure	46,269	49,099	49,580	53,036	58,134	59,185	60,032	59,851	1,97,984	2,37,202	57,437	
EBITDA	**16,415**	**21,376**	**22,095**	**21,711**	**24,635**	**22,113**	**18,033**	**16,783**	**81,597**	**81,563**	**21,460**	14.8
YoY Change (%)	20.6	72.8	60.5	68.0	50.1	3.4	-18.4	-22.7	54.9	0.0	30.7	
Margins (%)	26.2	30.3	30.8	29.0	29.8	27.2	23.1	21.9	29.2	25.6	27.2	
Depreciation	2,990	3,168	3,130	3,589	4,529	4,635	4,451	4,370	12,876	17,985	3,531	
EBIT	**13,425**	**18,208**	**18,965**	**18,122**	**20,106**	**17,477**	**13,582**	**12,413**	**68,721**	**63,579**	**17,929**	
YoY Change (%)	20.5	85.8	71.6	101.6	49.8	-4.0	-28.4	-31.5	67.7	-7.5	33.6	
Margins (%)	21.4	25.8	26.5	24.2	24.3	21.5	17.4	16.2	24.6	19.9	22.7	
Interest	918	1,076	1,150	1,202	1,096	1,001	981	932	3,851	4,011	981	
Other Income	790	900	1,147	1,407	1,303	1,336	1,283	1,260	3,450	5,182	820	
EO Exp/(Inc)	-859	-2,037	3,742	-953	139	0	0	0	-106	139	0	
PBT	**14,156**	**20,070**	**15,220**	**19,280**	**20,174**	**17,813**	**13,884**	**12,741**	**68,427**	**64,611**	**17,768**	
Tax	1,941	5,221	3,415	4,593	6,004	4,560	3,679	3,122	15,171	17,365	4,087	
Rate (%)	13.7	26.0	22.4	23.8	29.8	25.6	26.5	24.5	22.2	26.9	23.0	
Minority Interest	-24	-69	-50	-83	-20	-55	-55	-55	-226	-222	-55	
Reported PAT	**12,191**	**14,779**	**11,756**	**14,604**	**14,150**	**13,198**	**10,150**	**9,565**	**53,329**	**47,062**	**13,626**	
Adj PAT	**11,450**	**13,272**	**14,658**	**13,879**	**14,248**	**13,198**	**10,150**	**9,565**	**53,258**	**47,159**	**13,626**	4.6
YoY Change (%)	27.4	72.8	71.4	85.7	24.4	-0.6	-30.8	-31.1	62.9	-11.5	19.0	
Margins (%)	18.3	18.8	20.5	18.6	17.2	16.2	13.0	12.5	19.0	14.8	17.3	
EPS	**25**	**29**	**32**	**30**	**31**	**29**	**22**	**21**	**117**	**103**	**30**	4.6

Key performance Indicators (Consolidated)


Y/E March	FY26				FY27E				FY26	FY27E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Domestic formulations	20,894	20,777	20,387	19,082	23,796	23,582	23,241	21,849	81,140	92,468
YoY Change (%)	7.8	3.4	5.6	11.5	13.9	13.5	14.0	14.5	6.9	14.0
US formulations	24,041	27,624	31,132	33,987	34,348	32,744	29,106	28,048	1,16,784	1,24,246
YoY Change (%)	24.3	47.3	54.0	56.9	42.9	18.5	(6.5)	(17.5)	46.0	6.4
Other developed markets	7748	8117	8121	8453	11494	11320	11488	11984	32439	46286
YoY Change (%)	17.4	18.9	10.8	22.2	48.3	22.0	24.0	25.0	17.2	42.7
Emerging markets	6524	9228	9170	9906	9897	10231	11043	11388	25978	28853
YoY Change (%)	5.2	45.3	42.4	48.7	51.7	10.9	20.4	15.0	1.3	11.1
API	2,431	2,568	2,195	2,491	2,637	2,645	2,412	2,591	9,685	10,285
YoY Change (%)	(32.9)	(12.8)	(24.1)	7.6	8.5	3.0	9.9	4.0	(17.7)	6.2
Cost Break-up										
RM Cost (% of Sales)	28.3	25.9	26.2	24.8	25.2	26.5	26.9	28.8	26.7	26.9
Staff Cost (% of Sales)	17.3	15.7	16.0	16.6	16.7	16.3	17.9	18.5	16.6	17.4
R&D Expenses(% of Sales)	7.7	7.2	7.5	7.9	7.3	8.0	8.1	8.3	7.7	7.9
Other Cost (% of Sales)	20.5	20.9	19.6	21.7	20.9	22.0	24.0	22.5	21.0	22.4
Gross Margins(%)	71.7	74.1	73.8	75.2	74.8	73.5	73.1	71.2	73.3	73.1
EBITDA Margins(%)	26.2	30.3	30.8	29.0	29.8	27.2	23.1	21.9	29.2	25.6
EBIT Margins(%)	21.4	25.8	26.5	24.2	24.3	21.5	17.4	16.2	24.6	19.9

Highlights from the management commentary

- Management expects FDA approval for Apixaban 505(b)(2) in Sep'26 and commercial launch in summer CY27, with an expected 10–12-month exclusivity period before generic entrants in FY29.
- LPC plans to launch 50+ products in the US over the next three years, including 10 first-to-file opportunities, five biosimilars and 2-3 505(b)(2) products; 15+ filings are planned in FY27, including at least seven respiratory products, while Raltegravir is expected to be an exclusive launch in FY27.
- Management remains focused on increasing the contribution of complex products in the US, led by respiratory, complex injectables and biosimilars.
- Management highlighted stable pricing across the European portfolio and expects biosimilar growth to be supported by favorable regulatory developments in Germany and France.
- Management expects India formulations to outperform IPM by 1.2-1.3x, supported by a ~11,300-member prescription sales force and 80+ product launches over the next three years.
- Management indicated that only 3-4 of the 80+ planned launches over the next three years will be innovative products, while 60-70 innovative product launches are planned over the next 10 years.
- LPC targets chronic therapies to contribute 70% of the India portfolio over the next five years (vs. 67% currently) and novel proprietary products to contribute one-third of India revenue over the next 10 years.
- In-licensed products contributed ~6% of India business revenue in 1QFY27.
- India core prescription business grew 15.1% YoY (1.1x IPM) with 6.1% volume growth in 1QFY27.
- Management expects continued healthy growth in the India diabetes portfolio, supported by vial and oral semaglutide launches in 2HFY27, following the second consecutive quarter of 20%+ growth driven by human insulin and semaglutide injection.
- LPC delivered 20%+ organic growth in the ex-US business during 1QFY27.


Key exhibits

Exhibit 1: US sales increased 42.9% YoY in 1QFY27



Source: MOFSL, Company

Exhibit 2: DF sales up 13.9% YoY in 1QFY27



Source: MOFSL, Company

Portfolio expansion and launches to drive sustainable growth

US – Complex generics, respiratory portfolio and biosimilars to drive growth

- 1QFY27 US sales grew 43% YoY to INR34.3b (30% YoY in CC to USD366m), driven by base business volume growth, recent launches and improved portfolio mix.
- LPC received six ANDA approvals and launched three products during the quarter, taking its marketed US generic portfolio to 149 products.
- The company continues to hold the #3 position in the US generic market by prescriptions, with 56 market-leading products and 112 products ranked among the top three.
- Pipeline remains robust with 15+ planned launches and 15+ ANDA filings in FY27, 50 First-to-File opportunities (including 21 exclusives), 45+ injectable and 20+ inhalation products under development.
- Biosimilars remain an important growth pillar, with plans to launch 5+ biosimilars by FY31, while the company continues to expand its specialty portfolio through products such as Xopenex and NaMuscla.
- Investments continue in complex generics, inhalation, injectables and 505(b)(2) products, with a target of deriving 65%+ of new product launch revenue from complex products by FY31.
- We expect a 4% CAGR in US revenue over FY26-28E, as incremental launches and base portfolio growth are likely to be largely offset by continued price erosion, higher competition and product-specific LOE impacts, with complex generics and biosimilars providing gradual support over the medium term.

DF - Chronic-led growth supported by portfolio expansion

- 1QFY27 India sales grew 13.9% YoY to INR23.8b, driven by 15.1% YoY growth in prescription formulations, supported by continued outperformance in chronic therapies and new launches.
- Chronic portfolio continued to outperform with 21.5% YoY growth, while chronic contribution increased to ~67% of India sales (vs. ~65% in FY26), led by diabetes, cardiology and respiratory.
- Anti-diabetes business grew 31.8% YoY, significantly ahead of market growth, aided by strengthening diabetes franchise and GLP-1 preparations.

- LPC launched seven brands across therapies during the quarter and plans to launch 20+ products in FY27, supporting portfolio expansion.
- Sales force remains a key differentiator with ~11,300 field force (including ~8,700 medical representatives), while expansion continues in extra-urban markets, hospitals, organized retail and e-commerce channels.
- Consumer healthcare, diagnostics and digital health platforms continue to strengthen the broader healthcare ecosystem, with diagnostics serving 700k+ patients during the quarter.
- We expect India revenues to grow at 13% CAGR over FY26-28E, driven by sustained chronic outperformance, higher contribution from diabetes and respiratory, continued product launches, deeper market penetration, field force expansion and increasing contribution from adjacent healthcare businesses.

Other - Broad-based growth and expanding specialty portfolio

- Other Developed Markets (ODM) sales grew 48.3% YoY to INR11.5b, while Emerging Markets (EM) grew 51.7% YoY to INR9.9b in 1QFY27, reflecting broad-based growth across geographies.
- LPC received EMA approval for pediatric expansion of NaMuscla, launched Luforbec in Spain, and secured approval for Oseltamivir oral suspension in China, expanding its regulated market presence.
- Australia, Europe and Canada continue to benefit from operating leverage through common product platforms, while Latin America, South Africa, the Philippines and Southeast Asia remain key growth markets.
- Biosimilars and complex products are expected to become an increasingly meaningful contributor across regulated international markets, supported by global filings and commercialization plans.
- Oncology innovation also advanced with Phase-1 data for LNP8701 accepted for presentation at ASCO, strengthening the long-term innovation pipeline.
- We expect ODM & EM revenue to sustain healthy double-digit growth momentum over FY26-28E, driven by continued portfolio expansion in regulated markets, respiratory and specialty launches, biosimilar commercialization, broader geographic penetration and sustained demand across emerging markets.

Reiterate Neutral

- We reduce our earnings estimate by 6% for FY27 to factor in increased depreciation and a higher tax rate. We value LPC at 22x 12-month forward earnings to arrive at a TP of INR2,500.
- FY27 would be the year of consolidation after three years of strong earnings growth. LPC is implementing efforts to build a niche product pipeline in focus markets to improve the growth outlook going forward. This, supported with marketing efforts in select markets, is expected to strengthen overall growth for the company.
- Having said this, the earnings should remain stable over FY26-28 due to increased competition expected in certain products over near term and some gestation period to offset this impact, and subsequently return to growth path. Valuation provides limited upside from current levels. Maintain Neutral.

Story in charts

Exhibit 3: Revenue mix in 1QFY27




Exhibit 4: Expect 11% sales CAGR over FY26-28




Exhibit 5: R&D spending to inch up going forward




Exhibit 6: EBITDA margin to dip over FY26-28




Exhibit 7: Expect EPS to remain stable over FY26-28





Exhibit 8: 430 cumulative ANDAs filed



Source: MOFSL, Company,

Financials and valuations

Income Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Net Sales	**1,60,321**	**1,66,417**	**1,98,054**	**2,25,029**	**2,79,580**	**3,18,766**	**3,43,169**
Change (%)	6.2	3.8	19.0	13.6	24.2	14.0	7.7
EBITDA	**19,968**	**17,582**	**35,932**	**52,668**	**81,596**	**81,563**	**81,078**
Margin (%)	12.5	10.6	18.1	23.4	29.2	25.6	23.6
Depreciation	8,220	8,807	9,956	11,693	12,876	17,985	15,034
EBIT	**11,748**	**8,775**	**25,977**	**40,975**	**68,720**	**63,579**	**66,044**
Int. and Finance Charges	1,428	2,743	3,116	2,949	3,851	4,011	3,275
Other Income - Rec.	1,504	757	1,218	2,207	3,450	5,182	5,500
PBT before EO item	**11,824**	**6,790**	**24,079**	**40,234**	**68,319**	**64,750**	**68,270**
EO Expense/(Income)	25,550	-375	-147	834	-106	139	0
PBT after EO item	**-13,726**	**7,165**	**24,227**	**39,400**	**68,425**	**64,611**	**68,270**
Tax	1,372	2,688	4,867	7,087	15,171	17,365	16,043
Tax Rate (%)	-10.0	37.5	20.1	18.0	22.2	26.9	23.5
Less: Minority Interest	-183	-176	-211	-246	-226	-185	-310
Reported PAT	**-15,280**	**4,301**	**19,149**	**32,066**	**53,028**	**47,062**	**51,916**
PAT Adj for EO items	**8,699**	**3,915**	**18,875**	**32,698**	**53,258**	**47,159**	**51,916**
Change (%)	-26.2	-55.0	382.1	73.2	62.9	-11.5	10.1
Margin (%)	5.4	2.4	9.5	14.5	19.0	14.8	15.1

Consolidated Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	909	910	909	913	914	914	914
Total Reserves	1,20,624	1,23,695	1,41,992	1,71,122	2,23,568	2,77,947	3,28,533
Net Worth	**1,21,533**	**1,24,605**	**1,42,901**	**1,72,035**	**2,24,483**	**2,79,139**	**3,29,726**
Minority Interest	687	783	831	909	651	836	1,146
Deferred liabilities	711	738	-567	-6,053	-6,137	-3,460	-3,460
Secured Loan	6,147	4,153	3,115	20,820	21,908	19,408	16,408
Unsecured Laon	37,023	42,165	26,699	34,173	44,779	38,668	34,668
Total Loans	43,170	46,318	29,814	54,993	66,687	58,076	51,076
Capital Employed	**1,66,101**	**1,72,444**	**1,72,979**	**2,21,884**	**2,85,684**	**3,34,314**	**3,78,210**
Gross Block	95,368	1,05,127	1,17,618	1,31,807	1,47,692	1,54,667	1,61,830
Less: Accum. Deprn.	49,870	58,677	68,632	80,325	93,201	1,11,185	1,26,219
Net Fixed Assets	**45,498**	**46,450**	**48,986**	**51,482**	**54,491**	**43,482**	**35,611**
Capital WIP	8,475	8,948	5,957	3,555	6,952	6,826	6,763
Investments	9,000	5,169	10,747	13,840	15,462	15,462	15,462
Goodwill & Intangibles	31,306	40,534	41,566	47,323	58,657	58,657	58,657
Curr. Assets	**1,22,236**	**1,26,861**	**1,29,656**	**1,69,796**	**2,41,949**	**2,96,902**	**3,64,706**
Inventory	46,307	44,918	49,539	54,764	60,833	66,182	81,248
Account Receivables	42,619	44,807	46,920	54,971	66,041	77,064	84,337
Cash and Bank Balance	10,981	12,931	12,025	31,423	56,529	80,098	1,25,558
Others	22,328	24,205	21,171	28,638	58,547	73,558	73,563
Curr. Liability & Prov.	**50,414**	**55,519**	**63,931**	**64,111**	**91,826**	**87,015**	**1,02,988**
Account Payables	42,254	46,937	54,928	57,019	80,887	76,075	92,049
Provisions	8,160	8,581	9,003	7,093	10,939	10,939	10,939
Net Current Assets	**71,822**	**71,342**	**65,725**	**1,05,685**	**1,50,123**	**2,09,887**	**2,61,718**
Appl. of Funds	**1,66,101**	**1,72,444**	**1,72,979**	**2,21,884**	**2,85,684**	**3,34,314**	**3,78,210**

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EPS	**19.0**	**8.6**	**41.3**	**71.5**	**116.5**	**103.1**	**113.6**
Cash EPS	37.2	28.0	63.4	97.2	144.6	142.5	146.4
BV/Share	267.4	273.9	314.4	376.8	491.0	610.5	721.2
DPS	9.0	2.0	2.5	2.5	2.5	2.5	2.5
Payout (%)	-31.3	24.7	6.9	4.1	2.5	2.8	2.6
Valuation (x)							
P/E	124.2	276.1	57.3	33.1	20.3	22.9	20.8
Cash P/E	63.5	84.5	37.3	24.3	16.3	16.6	16.1
P/BV	8.8	8.6	7.5	6.3	4.8	3.9	3.3
EV/Sales	7.0	6.8	5.6	5.0	4.0	3.4	3.0
EV/EBITDA	56.5	64.2	31.0	21.3	13.6	13.2	12.6
Return Ratios (%)							
RoE	6.7	3.2	14.1	20.8	26.9	18.7	17.1
RoCE	8.6	3.5	12.6	17.7	21.7	16.0	15.2
RoIC	9.8	3.9	14.3	21.2	28.2	21.2	21.8
Working Capital Ratios							
Asset Turnover (x)	1.0	1.0	1.1	1.0	1.0	1.0	0.9
Fixed Asset Turnover (x)	3.6	3.6	4.2	4.5	5.3	6.5	8.7
Debtor (Days)	97	98	86	89	86	88	90
Creditor (Days)	129	136	163	158	208	193	190
Inventory (Days)	105	99	91	89	79	76	86
Leverage Ratio							
Current Ratio	2.4	2.3	2.0	2.6	2.6	3.4	3.5
Interest Cover Ratio	8.2	3.2	8.3	13.9	17.8	15.9	20.2
Debt/Equity (x)	0.3	0.3	0.1	0.1	0.0	-0.1	-0.2

Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
PBT Before EO items	-13,722	7,165	24,223	40,150	68,726	81,563	81,078
Int./Dividends Recd.	468	2,422	2,280	1,589	2,159	5,182	5,500
Direct Taxes Paid	469	-2,432	-3,261	-9,060	-12,674	-14,687	-16,043
(Inc)/Dec in WC	-150	3,265	855	-14,105	6,337	-36,196	-6,370
CF from Operations	**-12,936**	**10,420**	**24,098**	**18,573**	**64,548**	**35,863**	**64,164**
Others	16,609	8,552	12,386	11,426	8,797	2	2
EO expense	0	0	0	0	0	139	0
CF from Op. incl EO Exp.	**3,673**	**18,972**	**36,484**	**29,999**	**73,345**	**35,726**	**64,166**
(inc)/dec in FA	-8,980	-14,611	-9,166	-16,531	-19,122	-6,850	-7,100
Free Cash Flow	**-21,916**	**-4,191**	**14,931**	**2,042**	**45,426**	**29,013**	**57,064**
(Pur)/Sale of Inv.	15,891	3,958	-5,374	-324	-23,804	0	0
Others	6,011	-2,214	-2,582	-24,864	4,280	0	0
CF from Investments	**12,922**	**-12,868**	**-17,122**	**-41,719**	**-38,646**	**-6,850**	**-7,100**
Change in Net Worth	161	19	146	399	165	9,009	210
Inc/(Dec) in Debt	-11,693	700	-17,331	24,277	2,790	-8,611	-7,000
Interest Paid	-1,240	-2,267	-2,829	-2,295	-3,615	-4,011	-3,275
Dividend Paid	-2,951	-1,825	-1,828	-3,653	-5,483	-1,329	-1,329
Others	0	0	0	-1,409	-4,893	-122	-212
CF from Fin. Activity	**-15,723**	**-3,373**	**-21,842**	**17,319**	**-11,036**	**-5,065**	**-11,606**
Inc/Dec of Cash	**872**	**2,732**	**-2,481**	**5,599**	**23,663**	**23,811**	**45,460**
Add: Beginning Balance	9,262	9,913	12,317	9,836	31,423	55,087	78,898
Cash/Cash Eq.	10,134	12,645	9,836	15,436	55,087	78,898	1,24,358
Forex/Bank	-221	-328	0	15,988	1,442	1,442	1,442
Closing Balance	**9,913**	**12,317**	**9,836**	**31,423**	**56,529**	**80,097**	**1,25,558**

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

.

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

****

The associates of MOFSL may have:
financial interest in the subject company
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
received compensation/other benefits from the subject company in the past 12 months
any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
Served subject company as its clients during twelve months preceding the date of distribution of the research report.
The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.